BioLineRx (NASDAQ:BLRX – Get Free Report) was upgraded by investment analysts at StockNews.com to a “sell” rating in a research report issued on Monday. Separately, HC Wainwright restated a “buy” rating and set a $21.00 price objective on shares of BioLineRx in a research report on Monday, November 20th. Check Out Our Latest Analysis on […]
BioLineRx: Weighing Aphexda's Breakthrough Against Financial Challenges (NASDAQ:BLRX) seekingalpha.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from seekingalpha.com Daily Mail and Mail on Sunday newspapers.
BioLineRx (NASDAQ:BLRX) Announces Quarterly Earnings Results kopsource.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from kopsource.com Daily Mail and Mail on Sunday newspapers.
BioLineRx (NASDAQ:BLRX – Get Free Report) announced its earnings results on Monday. The biotechnology company reported ($0.30) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.12), MarketWatch Earnings reports. During the same period last year, the firm posted ($0.15) EPS. BioLineRx Price Performance BLRX opened at $1.52 on Wednesday. […]
BioLineRx (NASDAQ:BLRX) Announces Earnings Results themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.
BioLineRx (NASDAQ:BLRX – Get Free Report) announced its earnings results on Monday. The biotechnology company reported ($0.30) EPS for the quarter, missing the consensus estimate of ($0.18) by ($0.12), MarketWatch Earnings reports. During the same period in the previous year, the company earned ($0.15) earnings per share. BioLineRx Price Performance BLRX stock opened at $1.70 […]
Operator: Ladies and gentlemen, thank you for standing by. Welcome to the BioLineRx Third Quarter 2023 Financial Results Conference Call. All participants are presently in a listen-only mode.
M.S.Q. Ventures (MSQ) is pleased to announce that its client,BioLineRx Ltd.(BioLineRx) (NASDAQ/TASE: BLRX), has entered into an exclusive license agreement withGuangzhou Gloria Biosciences Co., Ltd.(GloriaBio) and an associated investor for the
MSQ Ventures: BioLineRx entered Exclusive License Agreement to Motixafortide in Asia, advisored by M.S.Q. Ventures finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
BioLineRx entered Exclusive License Agreement to Motixafortide in Asia, advisored by M.S.Q. Ventures kptv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from kptv.com Daily Mail and Mail on Sunday newspapers.